Hope S. Rugo, MD, describes how she would treat a patient with HER-positive metastatic breast cancer that has progressed with a CDK4/CDK6 inhibitor plus an aromatase inhibitor.
Related Items
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
TON Web Exclusives published on February 26, 2018 in Breast Cancer
TON Web Exclusives published on February 26, 2018 in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
JHOP - December 2017 Vol 7, No 4 published on February 26, 2018 in Breast Cancer
Last modified: March 9, 2018